Picture of WW International logo

WW — WW International News Story

0.000.00%
us flag iconLast trade - 00:00
Consumer DefensivesSpeculativeSmall CapTurnaround

WW International Q2 revenue beats estimates on Clinical growth

WW International Q2 revenue beats estimates on Clinical growth


Overview

  • Weight management platform's Q2 revenue beat expectations as Clinical subscription revenue grew

  • Core+ Behavioral tier posted third consecutive quarter of sequential subscriber growth

  • Company reaffirmed full-year 2026 revenue and adjusted EBITDA guidance


Outlook

  • WW International reaffirms 2026 revenue guidance of $620 mln to $635 mln

  • Company maintains 2026 adjusted EBITDA guidance of $105 mln to $115 mln

  • WW International sees continued momentum in Core+ and Clinical subscriber growth


Result Drivers

  • CLINICAL GROWTH - Clinical Subscription Revenue rose 30.4% yr/yr and Clinical subscribers increased 55.7%, despite lapping significant prior-year growth

  • CORE+ SUBSCRIBER GAINS - Core+ Behavioral tier posted third consecutive quarter of sequential subscriber growth, up 13.9% yr/yr

  • MIX SHIFT TO CLINICAL - Monthly subscription revenue per average subscriber increased 10.2% yr/yr, driven by shift toward Clinical offerings


Company press release: ID:nGNX4Srl03


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$162.30 mln

$159.15 mln (2 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the personal services peer group is "buy."

  • Wall Street's median 12-month price target for WW International Inc is $30.00, about 81.6% above its August 4 closing price of $16.52


Reuters Recommended Reads

  • Aug 3 - Medifast Q2 revenue falls 28% as active coaches drop

  • Aug 3 - Obesity battle heats up again as Novo claws way back into race with Lilly

  • Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on WW International

See all news